Skip to content

INDEPENDENT EQUITY RESEARCH

  • The Program
  • Reports
  • About Us
  • Contact us
  • The Program
  • Reports
  • About Us
  • Contact us
  • The Program
  • Reports
  • About Us
  • Contact us

INDEPENDENT EQUITY RESEARCH

Read more about the article Oramed Pharmaceuticals Inc.: Sufficient funds for clinical development activity over the next 24 months; several clinical milestones are scheduled for 2018 and 2019; as Oramed’s clinical progress meets our expectations, stock target price remains at NIS 53.2.
Oramed Pharmaceuticals (PRNewsFoto/Oramed Pharmaceuticals Inc)

Oramed Pharmaceuticals Inc.: Sufficient funds for clinical development activity over the next 24 months; several clinical milestones are scheduled for 2018 and 2019; as Oramed’s clinical progress meets our expectations, stock target price remains at NIS 53.2.

  • Post author:jaimeuss_admin
  • Post published:6 בSeptember 2018
  • Post category:Research
  • Post comments:0 Comments

Continue ReadingOramed Pharmaceuticals Inc.: Sufficient funds for clinical development activity over the next 24 months; several clinical milestones are scheduled for 2018 and 2019; as Oramed’s clinical progress meets our expectations, stock target price remains at NIS 53.2.
INDEPENDENT EQUITY RESEARCH

Tel: +972(0)9.950.2888
Email: equity.research@frost.com

Contact us

Copyright © 2020 Frost & Sullivan. All Rights Reserved.   Privacy Policy.

Accessibility by WAH